We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Continuous Glucose Sensor Aids Diabetics

By HospiMedica staff writers
Posted on 07 Apr 2006
A medical device that continuously monitors glucose will greatly improve the quality of diabetes care and lower the risk of complications such as loss of sight, heart attacks, kidney failure, and amputation. More...
It is an important step toward the development of an artificial pancreas for people suffering from diabetes.

The Juvenile Diabetes Research Foundation (JDRF, New York, NY, USA), a charitable supporter of research on type 1 diabetes, has announced that a new device, the Short Term Sensor (STS) continuous glucose monitoring system, has been approved by the U.S. Food and Drug Administration (FDA). Developed by DexCom Inc., (San Diego, CA, USA), the monitoring system is a patient-insertable short-term sensor that wirelessly transmits blood-glucose readings to a handheld receiver.

The wire-like sensor is inserted via an applicator by the user or clinician just under the skin and held in place by an adhesive to the skin. Once inserted, the user wears the sensor for up to three days when the patient removes and discards it. A new sensor is then used with the same receiver. The STS receiver provides continuous glucose values, one-, three-, and nine-hour glucose trend information, high- and low-glucose alerts, and low-glucose alarm. The patient is able to adjust medication, diet, and exercise according to the glucose levels.

Monitors such as these are the keys to the development of a closed-loop glucose testing and insulin delivery system, or an "artificial pancreas.” Closed loop technology will provide patients with far more information about their daily glucose fluctuations and trends and allow for far-tighter control. Patients who aggressively manage their diabetes typically test their glucose levels up to eight times a day, and provide insulin injections based on that information. The artificial pancreas will test the glucose approximately 1,400 times a day, and make insulin available based on real-time information.

"The development of an artificial pancreas has been one of JDRF's top research goals, and we are cautiously optimistic that these new products will be as successful and beneficial to people with diabetes as we hope,” said Aaron Kowalski, Ph.D., Director of research projects at JDRF.



Related Links:
JDRF
DexCom

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gold Member
Blood Gas Analyzer
i-Check200
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.